Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables.
Open Access
- 1 December 1993
- Vol. 34 (12) , 1714-1717
- https://doi.org/10.1136/gut.34.12.1714
Abstract
Pretreatment variables that could predict the response of chronic hepatitis C to interferon alfa treatment have not been fully assessed. Eighteen baseline variables were evaluated in a series of 100 consecutive patients treated with a 12 month course of interferon alfa. For the purposes of this study, response was defined as the return to normal of aminotransferase activities before the third month of treatment. Seventy per cent of the patients responded to treatment. Six variables were associated with an increased likelihood of response assessed by univariate analysis. With stepwise multiple regression analysis assessment, however, only three variables remained independently predictive of response: low gamma glutamyltransferase (gamma GT) activities (p < 0.001), absence of obesity (p = 0.005), and absence of cirrhosis (p = 0.01). The response rate in patients with gamma GT activities < 0.66 mu kat/l (n = 55) was 78% and 60% in patients with values > 0.66 mu kat/l (n = 45) (p = 0.048). Response was attained in 75% of non-obese patients (n = 80), compared with only 50% of obese patients (n = 20) (p = 0.03). Finally, 80% of patients without cirrhosis (n = 76) responded, while among those with cirrhosis (n = 24) the response rate was only 37% (p < 0.001). All 23 patients without cirrhosis, 0.66 mu kat/l responded to interferon alfa (p<0.001). Those findings may be useful when evaluating interferon alfa trials and it is suggested that this treatment should be applied early in the course of chronic hepatitis C.Keywords
This publication has 21 references indexed in Scilit:
- Randomised trial of lymphoblastoid α-interferon in chronic hepatitis C: Effects on inflammation, fibrogenesis and viremiaJournal of Hepatology, 1993
- Interferon for non-A, non-B chronic hepatitis: A meta-analysis of randomised clinical trialsJournal of Hepatology, 1991
- Influence of skinfold thickness on heparin absorptionThe Lancet, 1991
- Recombinant α-interferon treatment of non-A, non-B (type C) hepatitis: review of studies and recommendations for treatmentJournal of Hepatology, 1990
- Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis. Preliminary results of a randomized, controlled trialJournal of Hepatology, 1990
- Is the response to recombinant alpha interferon related to the presence of antibodies to hepatitis C virus in patients with chronic non-A,non-B hepatitis?Journal of Hepatology, 1990
- Experimental colorectal liver metastasesJournal of Hepatology, 1990
- Recombinant Interferon Alfa Therapy for Chronic Hepatitis CNew England Journal of Medicine, 1989
- Treatment of Chronic Hepatitis C with Recombinant Interferon AlfaNew England Journal of Medicine, 1989
- A Randomized Controlled Open Study of Interferon Alpha-2b Treatment of Chronic IMon-A, Non-B Posttransfusion Hepatitis: No Correlation of Outcome to Presence of Hepatitis C Virus AntibodiesScandinavian Journal of Infectious Diseases, 1989